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Abstract
Introduction The authors compared the oncologic out-
comes of radiofrequency ablation (RFA) with robotic-as-
sisted partial nephrectomy (RPN) for the treatment of T1
stage renal cell carcinoma (RCC).
Materials and methods This was a retrospective data
analysis of a high-volume single tertiary centre. Patients
were treated with RFA or RPN following multidisciplinary
decision making. Only histologically proven RCCs were
included. Baseline demographics were collected, and
PADUA scores of tumour features were calculated to
standardize baseline anatomy. Peri-operative complica-
tions, kidney function and oncological outcomes were
compared.
Results Sixty-three cases were included in each group.
Baseline renal function was poorer in RFA, and 16/63 RFA
patients had tumours in single kidneys compared to 1/63
RPN cases (p\ 0.001). Length of stay was shorter in RFA
(1 vs. 3 days, p\ 0.0001). Post-procedure renal function
decline at 30 days was significantly less in RFA
[(-0.8) ± 9.6 vs. (-16.1) ± 19.5 mls/min/1.73 m2;
p\ 0.0001]. More minor complications were recorded in
RPN (10/63 vs. 4/63, p = 0.15), but local recurrence was
numerically higher in RFA (6/63 vs. 1/63, p = 0.11).
Disease-free survival (DFS) was not significantly different
(adjusted HR = 0.6, 95 % Cl 0.1–3.7; p = 0.60).
Increasing tumour size was an independent predictor of
local recurrence (adjusted HR = 1.7; 95 % Cl 1.1–2.6
per cm; p = 0.02).
Conclusions Both RPN and RFA offer very good onco-
logical outcomes for the treatment of T1 RCC with low
peri-operative morbidity and similar oncologic outcomes.
RFA demonstrated fewer peri-operative complications and
better preservation of renal function, whereas RPN had an
insignificantly lower local recurrence rate. RFA should be
offered alongside RPN for selected cases.
Keywords Radiofrequency ablation  Robotic partial
nephrectomy  Renal cell carcinoma  Local
recurrence  Disease-free survival
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Introduction
With increasing numbers of renal cell carcinomas (RCC)
being diagnosed annually, clinicians and researchers are
continuously looking for ways to evaluate and find the
most optimal treatments for RCC [1]. Current clinical
practice has moved a long way in the past decade from
open nephrectomies to laparoscopic partial nephrectomies
and a current focus on robotic-assisted partial nephrec-
tomies and other nephron sparing procedures such as
radiofrequency thermal ablation [2]. This trend has evolved
due to an effort to reduce peri-operative complications and
maximise residual kidney function [3]. Current clinical
practice dictates that partial nephrectomy remains the
treatment of first choice for T1 small renal tumours
(\7 cm) and that radiofrequency ablation should be
reserved for a patient population deemed unfit for surgery,
such as elderly patients, those with significant comorbidi-
ties, those with positive family history of recurrent tumour
growth and those with solitary kidneys [4, 5].
Despite the several promising advantages offered by
thermal ablation and other minimally invasive nephron-
sparing techniques, clinicians hesitate to offer it as first-line
treatment due to the uncertainty relating to its long-term
oncological outcomes [1, 4]. This may be partly due to the
fact that there is a lack of long-term follow-up and com-
parison of oncological control in patients undergoing
radiofrequency ablation versus those undergoing partial
nephrectomy [6]. A preliminary search of the literature has
revealed only a small number of studies that examined
long-term outcomes and directly compared RFA with RPN
for the treatment of RCC [1–3, 6, 7]. There is a significant
need to compare the mid- to long-term oncological and
functional outcomes of RPN versus RFA in an effort to
establish the efficacy of the two treatments. Such a com-
parison will make it possible to assess whether the current
practice is optimal and to determine whether a less invasive
approach should be pursued.
Materials and Methods
Patient Sample
This was a retrospective data analysis (clinical audit) of the
RCC databases of a single tertiary centre and was approved
by the Institutional Review Board for quality improvement
purposes. Patients were triaged to either RFA or RPN
according to the decision of themultidisciplinarymeeting on
the basis of tumour size, underlying comorbidities and
patient preference. In our institution, patients with stage 1a
renal tumours (\4 cm) are routinely offered either RFA or
RPN and consented accordingly; patients with single kid-
neys and/or underlying comorbidities are most often offered
RFA, whereas patients with larger tumours ([4 cm; stage
1b) are routinely treated with RPN or open partial nephrec-
tomy or laparoscopic radical nephrectomy, with thermal
ablation reserved for frail patients or those with underlying
comorbidities. Large renal tumours treated with open partial
or radical nephrectomy were not included in the present
audit. In addition, only histologically proven RCCs were
included in our analysis (Table 1). Benign tumours, such as
angiomyolipomas and oncocytomaswere excluded from this
study. Data cleaning was subsequently performed to remove
any duplications, outliers and cases lost to follow-up. In total,
159 cases were audited; 22 cases with benign tumour his-
tology (angiomyolipomas and oncocytomas) and 11 cases
with incomplete and/or missing records were excluded from
further analysis. Finally, 126 cases were identified to fulfil
the inclusion criteria (Table 1), sixty-three of whom under-
went robotic-assisted partial nephrectomy (RPN) and sixty-
three of whom underwent radiofrequency ablation for T1
RCC between the 5 December 2005 and 23 November 2013
(study flowchart; Fig. 1). Patient comorbidities were evalu-
ated using the ASA (American Society of Anaesthesiolo-
gists) complications score [8]. The presence of solitary
kidney in the two groups and the level of baseline renal
function was also analyzed.
Treatment Techniques
RPN was performed laparoscopically using the da Vinci
Robot, Si Dual console as described elsewhere [9, 10].
Briefly, RPN starts by laparoscopically placing the robotic
ports and camera in the patient’s abdomen and reflecting
the bowel away from the surgical site. The renal vessels are
then recognized and protected using slings. Following this,
the kidney is mobilized by the surgeon, and the renal fat is
reflected completely, except for over the tumour margins.
Subsequently, the renal vessels are clamped when
Table 1 Inclusion and exclusion criteria for cases selection




All types of benign tumours (e.g.
AMLs)
T1 stage RCC (\7 cm) [7 cm renal tumours











Other types of ablation (e.g.
cryoablation)
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recording of warm ischaemic time (WIT) begins. The
tumour is then resected and a deep tumour biopsy is
sometimes performed. Renorrhaphy then follows, aiming
to minimize the WIT to less than 20 min [11]. This group
represented the initial series of RPN at our institution.
Radiofrequency ablation was performed percutaneously
under CT guidance using Covidien cool-tip electrodes,
which can produce a frequency of 480 Hz and power
output of 200 W as described elsewhere [12, 13]. Straight
monopolar electrodes were used, with a 17G needle. These
electrodes have an internal cooling system, which allows
slower rate of heating of nearby tissue and avoids car-
bonisation. A 17G needle was inserted under CT guidance
and ablation times aimed to produce an ablation zone
expanding 0.5–1.0 cm beyond the CT-determined tumour
diameter [12]. All tumours were ablated for at least one
cycle of up to 12 min in duration per instructions for use.
Transcatheter embolization is not routinely offered in our
institution as combination therapy for large-stage Ib renal
masses. Instead, multiple overlapping cycles are applied in
cases of tumours larger than 3 cm in order to produce an
additive ablation volume of the required size [12]. Prior to
each ablation, a percutaneous renal biopsy was performed
using an 18G TruCut needle for histological analysis [5].
We do not usually ablate the percutaneous tract because we
do not consider the risk of tract seeding to be high and are
unconvinced about the effectiveness of this approach.
However, in all cases, there is overlap of the ablation
volume with some of the surrounding perirenal fat in order
to obtain a healthy tissue margin.
After RFA, contrast-enhanced CT was performed the
next day to assess the technical result of the ablation
procedure. Follow-up included contrast-enhanced com-
puted tomography in patients who had RFA or transab-
dominal ultrasound in those treated with RPN every
4–6 months during the 2 years and annually thereafter. In
cases of local recurrence, the radiological diagnosis was
based on recurrent contrast enhancement, and repeat
ablation or open/laparoscopic nephrectomy was performed
without repeat biopsy [5].
Baseline Variables
The PADUA (pre-operative aspects and dimensions used
for an anatomical) classification was used to score the renal
tumours treated by both techniques [14, 15]. It was decided
that calculating a PADUA score for both RFA and RPN
groups would offer standardization of baseline anatomy
among the two groups and allow direct comparison. Under
the PADUA classification, renal tumours were divided and
scored according to six anatomical characteristics:
tumour’s longitudinal classification, the location of its
margin, its relationship with the renal sinus and the col-
lecting system, and the parenchymal depth and size
[14, 15]. BrillianceTM Workspace Portal software V.2.6.1.5
(Philips), CT Workstation, was used to reformat the renal
CT images and obtain the sagittal and multiplanar views
necessary for the calculation of the PADUA score. The
PADUA classification did not only enable us to standardize
and compare the RCC tumours between the two groups but
also allowed a reliable prediction of peri-operative risks.
Higher PADUA scores are associated with greater peri-
operative risks [16]. For example, a tumour with a PADUA
score of 12a, which is entirely endophytic and invading the
Fig. 1 Flowchart of
retrospective analysis of RFA
and RPN cases from the RCC
database maintained in a tertiary
teaching hospital centre
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urinary collective system will be more challenging to
excise or ablate than a tumour with a score of 7a, which
is[50 % exophytic and is remote from the urinary col-
lecting system [15].
Peri-procedural variables were retrospectively analysed
for both RFA and RPN cases in order to establish whether
there were any significant differences in the short- and mid-
to long-term post-operative complications using the Cla-
vien complications grading system [17]. Other parameters
investigated included serum biochemistry, baseline and
post-operative renal function and differences in hae-
moglobin plasma concentration pre- and post-procedure.
Serum creatinine was measured within 30 days post-pro-
cedure. Post-intervention follow-up consisted of clinical
history taking, physical examination, establishing the
existence of any short- or mid- to long-term complications
post-operatively and regular contrast-enhanced CT exami-
nations. The following parameters were analysed at follow-
up: signs of residual disease or local recurrence (including
tract seeding during RFA), new tumour growth (in the
same or other kidney), metastatic disease and whether the
patient received any other treatment. The primary purpose
of this study was to compare the disease-free survival
(DFS) between the two groups.
Endpoints and Statistical Methods
Clinical endpoints were used in conjunction with defini-
tions applied by the National Cancer institute (NCI) and the
European Association of Urology (EAU) guidelines on
renal cell carcinoma [4, 5]. Residual disease and positive
margins were defined histologically and governed the need
for further treatment. Local recurrence was defined as new
contrast enhancement within the RFA ablation zone or the
RPN treated area on follow-up CT or MR on the basis of
standard radiological criteria [5]. Tumour seeding within
the renal bed (following partial nephrectomy) or along the
needle tract (in patients treated with RFA) was analysed in
a similar way to local recurrence. Metastasis was defined as
evidence of biopsy-proven disease elsewhere in the body
that has originated from the treated kidney. Disease-free
survival was defined as the percentage of patients free from
any recurrence and metastasis on follow-up [4, 5].
Baseline demographics were analysed using the Chi-
square test for categorical variables and Fisher’s exact test
as applicable. Continuous data that showed normal distri-
bution, such as patient age, were evaluated using t test.
Non-parametric data were analysed using the Mann–
Whitney ‘U’ test. Disease-free Survival was analysed with
the Kaplan–Meier method. Survival curves for the two
groups were compared using the log-rank test and corre-
sponding hazard ratios were calculated. Cox regression
analysis (proportional hazards model) was used to produce
a survival function that would predict the probability of the
event of interest (e.g. local recurrence) occurring at a given
time t for given values of the predictor variables (con-
founders). Regression covariates included baseline tumour
size, PADUA score, age and type of treatment offered
(RFA vs RPN). The StatsDirect (version 2.7) and the
GraphPad Prism (version 6.0) software systems were used
for statistical analysis, and a p value of\0.05 (at 95 %
confidence interval) was taken as statistically significant.
Results
Our sample consisted of 63 patients in each group, a total
of 126 patients who met our inclusion criteria (Table 1).
Table 2 demonstrates our sample’s baseline characteristics.
The RPN group was significantly younger (p\ 0.0001),
and the majority of patients had an ASA score of B2
(p = 0.14). Mean tumour size was significantly different in
the two groups (p = 0.0003). However, the PADUA score,
which takes into account tumour size as well as anatomical
characteristics that can affect complexity and complica-
tions of the treatment, showed no significant difference
between the two groups (p = 0.69). Furthermore, the RFA
group consisted of 16 cases with a single kidney as
opposed to only one in the RPN group (p = 0.0002). The
baseline renal function was significantly poorer in the RFA
group (51.5 ± 20.0 mls/min/1.73 m2) compared to the
RPN group (87.8 ± 15.1 mls/min/1.73 m2). In addition,
the RFA group included two patients with documented von
Hippel Lindau disease (both had retinal haemangioblas-
tomas) and three cases with multiple small renal tumours
(2, 2 and 4 discrete lesions, respectively, all\2.0 cm). All
multifocal renal tumour cases had undergone unilateral
total nephrectomy previously and were treated with
sequential RFA sessions for nephron sparing purposes. The
majority of tumours were histologically proven clear cell
carcinomas in both RFA and RPN groups (Table 2).
Table 3 outlines the peri-procedural variables, and pro-
cedure-related complications calculated using the Clavien
complications score. Mean drop in Hb concentration was
significantly higher in the RPN group (p\ 0.0001). Both
Creatinine (Cr) increase and Glomerular Filtration rate
(GFR) decrease were higher in the RPN group in keeping
with a greater insult to the kidney. Early post-procedure
renal function decline at 30 days was significantly less in
RFA [(-0.8) ± 9.6 vs. (-16.1) ± 19.5 mls/min/1.73 m2;
p\ 0.0001]. Pre- and post-operative renal function in the 2
groups is illustrated in Fig. 2. Analysis of procedural
variables revealed no conversions to open surgery and no
blood transfusions in either group. Moreover, most RFA
cases were performed as procedures with a single overnight
stay as opposed to a median three-day hospital stay in the
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RPN group (p\ 0.0001). Clavien complication grading
system showed a similar minor complication rate with no
significant difference between the two groups (Table 3).
The median follow-up for the RFA group was signifi-
cantly longer than that for the RPN group, 4.0 vs. 1.5 year,
respectively (p\ 0.0001), because of the more recent
commencement of the RPN service (Table 4). Mid- to
long-term oncological outcomes including residual disease,
local recurrence, metastasis, as well as need for new or
repeat treatment were similar in the two groups and showed
no statistically significant differences (Table 4). In two
RFA cases, a residual enhancing tumour was identified on
the immediate post-operative scan and was treated suc-
cessfully with repeat ablation at 42 days and 2.5 months.
In one RPN case, tissue biopsy showed positive margins,
and further surgical excision was performed at the same
time. Local recurrence was numerically higher in the RFA
group, but not statistically significantly so (Table 4). In the
RFA group, there were 4 recurrences (2 in single kidneys,
one of which with multiple tumours at baseline) and 2
cases of tumour seeding that occurred after a median of
28 months (range, 8–84 months). There was no increased
incidence of local seeding or recurrence in RFA-treated
single kidneys (2 out of 16 vs. 4 out 47 cases, p = 0.64).
Table 2 Baseline
demographics
RFA RPN p value
Group size, n 63 63
Age (years), mean 61 ± 21 54 ± 7 \0.0001





Tumour size (cm), mean 2.11 ± 0.19 (range, 0.5–5.4) 2.88 ± 0.13 (range, 1.0–6.0) 0.0003
PADUA score, mean 7.27 ± 0.23 7.38 ± 0.16 0.69
Baseline eGFR 51.5 ± 20.0 87.8 ± 15.1 \0.0001
Single kidney, n 16/63 1/63 0.0002
Tumour histology (n)






RFA RPN p value
Hb change post procedure, (g/dL) (-0.3) ± 1.5 (-1.8) ± 0.85 \0.0001
sCr change post procedure, (lmol/L) (-6.3) ± 15.8 (-8.3) ± 18.8 0.36
eGFR change post procedure (mls/min/1.73 m2) (-0.8) ± 9.6 (-16.1) ± 19.5 \0.0001
Length of hospital stay (days; median, IQR) 1 (1–1) 3 (2–3) \0.0001
Minor complications (Clavien I and II) 4/63 10/63 0.15
Major complications (Clavien III and IV) 1/63 1/63 1.00
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Metastases developed in four patients (3 in RFA and 1 in
RPN; p = 0.62) after a median period of 37 months (range,
9–59 months).
Disease-free survival (DFS) was not significantly dif-
ferent between the two groups (HR = 0.84, 95 % Cl
0.19–3.4; p = 0.80; Fig. 3). Cox regression confirmed the
results with a non-significant adjusted HR = 0.6 (95 % Cl
0.1–3.7; p = 0.60) in favour of RPN (adjustment for
baseline tumour size, PADUA score, age and type of
treatment offered). On the other hand, tumour size had a
significant effect on DFS with increasing size found to be
an independent predictor of local recurrence (Cox adjusted
HR = 1.7; 95 % Cl 1.1–2.6 per cm of tumour size;
p = 0.02). The adjusted hazard ratio (HR) derived from the
Cox regression analysis is interpreted per unit of mea-
surement, i.e. per cm of tumour size. Hence, assuming
proportional hazards (Cox model), the hazard of recurrent
disease would increase by 1.7 times per centimetre of
original tumour size.
Discussion
Open partial nephrectomy has long been considered the
treatment of first choice for T1 small renal masses (SRMs)
[18]. Recently, there has been a move towards less invasive
procedures such as laparoscopic and robotic partial
nephrectomy [19, 20]. RPN seems to be the currently more
widely used method, in experienced centres, due to the
added benefits offered by the da Vinci robot (such as
improved precision and decreased range of motion) leading
to decreased warm ischaemic times [21]. RFA is considered
as an alternative treatment for T1 SRMs in those patients
with significant comorbidities (ASA score[2) and
advanced age [2, 5, 7]. In some cases, RFA is offered
alongside RPN as an adjunct, to the surgical procedure
according to baseline comorbidities. Moreover, the Euro-
pean Association of Urology (EAU) and the American
Urology Association (AUA) guidelines recommend partial
nephrectomy due to favourable long-term oncological out-
comes and lack of long-term RFA outcomes [4–6]. How-
ever, recent RFA studies have shown promising oncological
outcomes for carefully selected individuals, such as patients
with significant comorbidities as well as patients who could
have equally been candidates for RPN [1]. Due to the rel-
ative lack of studies where RFA is investigated as an
alternative or adjunct to RPN in carefully matched patient
groups, we felt the need to investigate this in detail [22].
By retrospectively comparing patients at a single tertiary
centre, we were able to match tumour sizes, PADUA
scores and comorbidity scores, and evaluate the mid- to
long-term outcomes with either treatment option. Baseline
demographics were well matched in both groups, but
comorbid conditions were slightly more pronounced in the
RFA group. Tumour size was significantly higher in the
Fig. 2 Boxplot of pre- and post-operative renal function (eGFR) in
the RPN (blue) and RFA (red) groups. The baseline renal function
was significantly poorer in the RFA group (*p\ 0.05). Post-operative
decline was significantly greater in patients treated with RPN
(*p\ 0.05)
Table 4 Long-term clinical outcomes
RFA RPN p value
Follow-up, months (median, range) 47.5 (11.8–80.2) 18.5 (6.2–29.5) \0.0001
Residual disease/positive margins (n) (repeat treatment performed) 2/63 1/63 1.00
Local recurrence/tract seeding (n) (repeat ablation or nephrectomy) 6/63 1/63 0.11
Renal cancer metastasis (n) 3/63 1/63 0.62
Fig. 3 Comparative Kaplan–Meier analysis of disease-free survival
between the RFA and RPN groups (unadjusted univariate hazard ratio
noted)
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RPN group, while significantly more single kidneys were
treated in the RFA group (Table 3). Overall disease-free
survival (DFS) was similar in the two groups (HR = 0.91),
with no statistically significant significance. One third of
local recurrences observed in the RFA group (2 out of 6
cases) were due to tract seeding during ablation (confirmed
radiologically), a well-known complication of the proce-
dure (Table 3). As one of the goals of RFA is to spare
normal renal parenchyma, and interventional radiologists
do not seek to ablate with large margins, it is possible that
this increases the risk of missed microscopic disease,
whereas in RPN larger tissue margins are usually excised.
The policy of minimizing the loss of normal renal par-
enchyma partly derives from the fact that RFA, unlike
RPN, can be repeated with minimal discomfort and risk to
the patient. The policy of sparing normal renal parenchyma
is even more important in patients with single kidneys as
one of the main aims of ablation is to minimize the risk of
the patient requiring hemodialysis.
Follow-up was significantly longer in the RFA group
because of a more recent establishment of the RPN service
(p\ 0.0001). It is notable that two local recurrences and
two late metastases were identified in the RFA group after
3 years, which was beyond the maximum follow-up period
in the RPN group. This may be due to the slow growth rate
of the disease and clearly indicates the need for ongoing
long-term follow-up (Table 4).
In addition, more minor complications were recorded in
the RPN group, but local recurrence and/or seeding was
more frequent in the RFA group (both non-significant
trends). The baselines demographic results partly reveal the
current treatment preferences among clinicians and patients
(Table 2). For example, the median age and ASA comor-
bidities score show that RFA was offered to older patients
and patients with more severe comorbidities (grades III–
V). Furthermore, RFA was routinely offered to patients
with von Hippel Lindau disease, multifocal tumours and
single kidneys (mostly following contralateral nephrec-
tomy), who may be associated with a higher risk of
recurrent or new tumours. Notwithstanding the fact that
RFA was offered to more frail patients with poorer baseline
renal function, the mid- to long-term clinical outcomes
compare well with those of robotic partial nephrectomy.
On the basis of these results, a case can be made for
offering this treatment to younger patients, those with
fewer comorbidities and those who prefer a less invasive
procedure [22]. Our results in relation to peri-operative
complications and mid- to long-term oncological outcomes
are similar to those of other individual studies solely
examining RFA or RPN [23, 24].
Certain strengths as well as limitations were unique to
our study and are worth discussing further. Firstly, our data
were retrospectively collected and analysed, raising the
possibility of selection bias. Arguably, the validity of our
results may have been limited by the discrepancy in follow-
up length between the two groups. This was outside this
study’s control, due to the later establishment of RPN in
comparison to RFA. The first RFA case performed at our
centre was in 2004 as opposed to 2010 for the first RPN
case. However, this was partly overcome by the more
regular basis at which RPN is currently performed, giving
us, thus, an adequate sample size. Secondly, our tertiary
centre has certain referral patterns, for example, with
referring urologists sending patients specifically for RPN or
local urologists referring older and frailer patients for RFA.
This might not be the case in other institutions, limiting the
generalizability of our results. Thirdly, there was a signif-
icant number of lost to follow-up, especially in RFA cases.
There are several factors contributing to this, most of
which were outside of our control (such as patients fol-
lowed up locally at other centres). This could have
undermined our previously stated results or limited our
sample of cases. Moreover, despite an adequate sample
size, the low number of post-operative events limited the
power of our statistical analysis.
A final limitation was the heterogeneous patient demo-
graphics of our two treatment groups. However, regression
analysis was employed to adjust for the confounders. In
addition, despite the promising oncological outcomes of
both techniques and overall disease-free survival, it is
worth noting that the success of both procedures is
dependent on very sub-specialized training, not currently
available at all tertiary training centres and requires
expertise for selecting the right patient population that
could potentially benefit from either procedure.
On the other hand, PADUA nephrometry scores enable
comparison of our results with future studies. In addition,
the use of a single technique for both RPN and RFA cases,
performed by the same clinical team eliminated any vari-
ability in treatment success evaluation (e.g. operator or
technique dependence). Furthermore, the fact that both
Urology and Interventional Radiology departments were
involved in this research as well as independent healthcare
professionals (not affiliated with either department) mini-
mized bias and strengthens the reliability of our results.
Despite the above limitations, our study succeeded in
confirming excellent oncological outcomes in RPN cases
and emphasizing similar comparable outcomes with RFA
in a selected group of patients. These results come with the
added advantage that a minimally invasive approach offers:
shorter hospital days, lower risk of intra-operative bleeding
and potential better preservation of renal function; still
little is known about long-term impact in residual renal
function and adaptive kidney mechanisms with either
technique. Therefore, RFA serves as an additional treat-
ment option for the experienced urologist who can
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carefully recommend it to appropriately selected patients
with small (T1) renal masses or as a future potential
adjuvant treatment alongside RPN [25]. In line with our
findings, comparable results between RFA and partial
nephrectomy were recently reported from other centres
both for localized stage 1a and for stage 1b renal tumours
[6, 26].
In conclusion, both robotic-assisted partial nephrectomy
and percutaneous radiofrequency ablation offer excellent
oncological outcomes for the treatment of T1 RCC with
low associated peri-operative morbidity. RFA was associ-
ated with fewer peri-operative complications and better
preservation of renal function, whereas RPN had an
insignificantly lower local recurrence rate. RFA could be
offered alongside RPN for selected cases. Prospective
randomized studies and subsequent meta-analyses in dif-
ferent age groups, PADUA classifications and histological
variants will help confirm the interchangeable use of these
two methods of treatment of small renal tumours.
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